Get the Stockscreener App
21.87
0.18%
-0.04
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Boosted by Great Point Partners LLC - MarketBeat
Algert Global LLC Has $2.61 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
TD Cowen Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - MSN
Viridian Therapeutics' SWOT analysis: biotech firm's stock poised for growth in TED market - Investing.com
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Now Covered by Analysts at TD Cowen - MarketBeat
TD Cowen bullish on Viridian stock—veligrotug’s potential in TED drives optimism - Investing.com UK
Eagle Asset Management Inc. Decreases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Principal Financial Group Inc. Purchases 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
B. Riley Forecasts Lower Earnings for Viridian Therapeutics - MarketBeat
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs - Nasdaq
HC Wainwright Has Bullish Forecast for VRDN FY2024 Earnings - MarketBeat
Viridian Therapeutics’ (VRDN) Buy Rating Reiterated at Needham & Company LLC - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $34.00 - Defense World
FY2024 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
What is Lifesci Capital’s Estimate for VRDN FY2024 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for VRDN FY2024 Earnings? - Defense World
(VRDN) Trading Signals - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Should You Sell? - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Viridian Ther - GuruFocus.com
Paradigm Biocapital Advisors LP Increases Stake in Viridian Ther - GuruFocus.com
Wedbush Expects Reduced Earnings for Viridian Therapeutics - MarketBeat
Leerink Partnrs Has Pessimistic View of VRDN FY2024 Earnings - MarketBeat
Lifesci Capital Has Bearish Outlook for VRDN FY2024 Earnings - MarketBeat
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $36.33 - MarketBeat
Viridian Therapeutics Inc (VRDN) Quarterly 10-Q Report - Quartzy
Brokers Set Expectations for VRDN Q1 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics stock target upgraded, keeps buy on veligrotug outlook By Investing.com - Investing.com Canada
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate - Simply Wall St
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses - TipRanks
Viridian Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
Viridian Therapeutics earnings missed by $0.09, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Business Wire
Stifel raises Viridian Therapeutics target to $41, keeps buy rating By Investing.com - Investing.com UK
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighTime to Buy? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Grants 150K Stock Options to New Employees in Retention Push | VRDN Stock News - StockTitan
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Net Present Value Model: Viridian Therapeutics Inc’s Veligrotug - GlobalData
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
Analyst Expectations For Viridian Therapeutics's Future - Fidelity Investments
Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Novo Holdings A S - MarketBeat
How To Trade (VRDN) - Stock Traders Daily
VRDN Factor-Based Stock Analysis - Nasdaq
Viridian Therapeutics' Superior Prospects Make It A Buy (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results - Insider Monkey
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):